Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.62 |
| ▸ | F2 | P00734 | 9/20 | 0.62 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.62 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6287358 | 0.90 | F10 (0.50) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6286203 | 0.86 | F10 (0.80) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7393756 | 0.82 | F10 (0.61) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6287100 | 0.77 | F10 (0.66) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6286596 | 0.76 | F10 (0.65) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6283141 | 0.76 | F2 (0.47) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8156355 | 0.76 | F10 (0.75) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6285870 | 0.68 | ALOX5AP (0.42) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7394185 | 0.67 | F10 (0.81) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8170777 | 0.65 | F10 (0.92) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | PRUITT JAMES RUSSELL (US) | 2004-04-15 | — | — | US | claimed |
| EP-0946528-B1 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-04-09 | — | — | EP | claimed |
| US-6962935-B2 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | PRUITT JAMES RUSSELL (US) | 2004-04-15 | — | — | US | disclosed |
| US-6569874-B1 | Such as 2-acetylamino-4-(3-amidinophenyl)-5-((2'-amino-sulfonyl-(1,1')-biphen-4 -yl)aminocarbonyl)thiazole; for treatment of thromboembolic disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-27 | — | — | US | disclosed |
| EP-0946528-B1 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-04-09 | — | — | EP | disclosed |
| US-6187797-B1 | ANTICOAGULANTS; TRYPSINE-LIKE SERINE PROTEASE INHIBITORS | DUPONT PHARMACEUTICALS COMPANY | 2001-02-13 | — | — | US | disclosed |
| EP-0946528-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028282-A2 | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073029-A1 | Oxygen or sulfur containing heteroaromatics as factor Xa inhibitors | F12, XDH, F2 | F10 18/4885F2 3/4885PRSS1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.